Kexing Biopharm Co., Ltd. Kexing Biopharm Co., Ltd.

Kexing Biopharm Co., Ltd.

688136

Rank in Stocks #12743
Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily... Kexing Biopharm Co., Ltd. is a global pharmaceutical enterprise primarily involved in the exploration, manufacturing, and commercialization of advanced recombinant protein-based drugs and microbial preparations, serving both the Chinese domestic market and international clientele. The company strategically directs its research and development endeavors towards crucial medical areas, specifically focusing on antiviral therapies, oncology, immunology, hematological conditions, digestive system health, and degenerative diseases. Its extensive product lineup features diverse pharmaceutical solutions. This includes innovative recombinant human proteins such as interferon a1b, erythropoietin, and granulocyte stimulating factor. Additionally, their offerings encompass microbial formulations like Clostridium butyricum combined live bacteria powder, traditional Chinese patent medicines (e.g., Kehuang Capsule), and chemical drugs like Entecavir. Kexing Biopharm also provides cutting-edge biologics, including liraglutide (a human glucagon-like peptide-1), along with other specialized therapeutics such as Albumin-Paclitaxel, Infliximab, Bevacizumab, adalimumab, trastuzumab, neratinib maleate tablets, and lenalidomide capsules. Established in 1989, the company's main operations are situated in Jinan, China.
Share Price
$2.11
Last synced: 2026-11-19
Market Cap
$418.16M
Change (1 day)
-2.86%
Change (1 year)
-53.78%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade Kexing Biopharm Co., Ltd. (688136)

Category

Healthcare
EPS for Kexing Biopharm Co., Ltd. (688136)
EPS as of September 2026 TTM: $0.06
According to Kexing Biopharm Co., Ltd.'s latest financial reports, its current EPS (TTM) is $0.06. At the end of 2025 the company had an EPS of $0.12, an increase over its 2024 EPS of $0.02.
EPS history for Kexing Biopharm Co., Ltd. from 2017 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $0.06 -51.25%
2025 $0.12 428.77%
2024 $0.02 -116.15%
2023 $-0.14 107.98%
2022 $-0.07 -184.57%
2021 $0.08 -45.86%
2020 $0.14 -7.35%
2019 $0.15 -31.35%
2018 $0.22 50.17%
2017 $0.15 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$15.66 26,669.23%
US
$-7.07 -12,185.47%
US
$-5.29 -9,142.74%
AU
$12.73 21,664.44%
BE
$21.56 36,754.70%
NL

Questions about Kexing Biopharm Co., Ltd.'s earnings per share (EPS)

What is Kexing Biopharm Co., Ltd.'s earnings per share (EPS)?

Kexing Biopharm Co., Ltd.'s earnings per share (EPS) over the last twelve months is $0.06, as of Sep 2026.

What was Kexing Biopharm Co., Ltd.'s earnings per share (EPS) in 2025?

In 2025, Kexing Biopharm Co., Ltd.'s earnings per share (EPS) was $0.12, 500.00% more than in 2024 ($0.02).

How has Kexing Biopharm Co., Ltd.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Kexing Biopharm Co., Ltd.'s earnings per share (EPS) went from $0.14 to $0.12, an average decline of 3.04% a year.

How does Kexing Biopharm Co., Ltd.'s earnings per share (EPS) compare with similar companies?

Kexing Biopharm Co., Ltd.'s earnings per share (EPS) ($0.06) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.